While Akero Therapeutics Inc has underperformed by -6.21%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKRO rose by 30.56%, with highs and lows ranging from $37.00 to $15.32, whereas the simple moving average jumped by 10.71% in the last 200 days.
On November 18, 2024, Citigroup started tracking Akero Therapeutics Inc (NASDAQ: AKRO) recommending Buy. Cantor Fitzgerald also rated AKRO shares as ‘Overweight’, setting a target price of $69 on the company’s shares in an initiating report dated September 19, 2023. UBS Initiated an Buy rating on August 28, 2023, and assigned a price target of $83. Morgan Stanley January 27, 2023d its ‘Equal-Weight’ rating to ‘Overweight’ for AKRO, as published in its report on January 27, 2023. Evercore ISI’s report from September 14, 2022 suggests a price prediction of $50 for AKRO shares, giving the stock a ‘Outperform’ rating. Morgan Stanley also rated the stock as ‘Equal-Weight’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Akero Therapeutics Inc (AKRO)
In order to gain a clear picture of Akero Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -35.90% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.25, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 582.00K can be a very valuable indicator of volatility for AKRO stock. On a monthly basis, the volatility of the stock is set at 5.08%, whereas on a weekly basis, it is put at 6.72%, with a loss of -5.40% over the past seven days. Furthermore, long-term investors anticipate a median target price of $48.90, showing growth from the present price of $28.71, which can serve as yet another indication of whether AKRO is worth investing in or should be passed over.
How Do You Analyze Akero Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.16%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AKRO shares are owned by institutional investors to the tune of 92.02% at present.
